vasopharm closes EUR9.5m financing round
vasopharm, a private biopharmaceutical company developing a new treatment for traumatic brain injury (TBI), has completed a EUR9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments. Existing investors Bayern Kapital, Future Capital, clients of Hanseatic Asset Management and Ringtons Holdings also participated in the round. In addition, vasopharm